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Abstract.
Background: Dementia is a spectrum of neurological diseases characterized by memory impairment and cognitive decline
with the pathogenesis and effective management remaining elusive. Several studies have identified a correlation between
anemia and Alzheimer’s disease and related dementias (ADRD); however, anemia subtypes and association with ADRD have
yet to be studied conclusively.
Objective: To study an association between ADRD and anemia of chronic inflammation.
Methods: We conducted a retrospective case-control study of the patients, diagnosed with ADRD at Brookdale Hospital.
Pair-wise comparisons between means of controls and cases in terms of iron studies and laboratory results were performed
using a Mann–Whitney U test. Pair-wise comparisons between anemia subgroups (moderate and severe) were performed
using a Two Sample proportion Z-Test, where for each couple of normally distributed population.
Results: There was a total of 4,517 (1,274 ADRD group; 3,243 Control group) patients. There was significant difference
in hemoglobin 10.15 versus 11.04 [p-value <0.001]. Iron studies showed a significant difference in ferritin 395 ± 488.18
versus 263 ± 1023.4 [p < 0.001], total iron binding capacity 225 ± 84.08 versus 266 ± 82.30 [p < 0.001] and serum iron level
64 ± 39.34 versus 53 ± 41.83 [p < 0.001]. Folic acid and vitamin B12 levels were normal in both groups. Severe and moderate
anemia in the ADRD group were respectively 6.2% [95% CI: 4.2–8.4] and 13% [95% CI: 9.8–16.2] higher. Overall, incidence
of moderate-to-severe anemia was found to be 19% higher in ADRD group [95% CI: 15.8–22.1].
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Conclusion: We demonstrated an association between ADRD and anemia of chronic inflammation independent of age, renal
function, and HgbA1C levels.
Keywords: Alzheimer’s disease, Alzheimer’s disease and related dementia, anemia, anemia of chronic inflammation, dementia
INTRODUCTION
Dementia consists of a broad spectrum of
neurological diseases characterized by memory
impairment and cognitive decline which dispropor-
tionately affects those in later stages of life. The
pathologies under the umbrella of dementia include,
but are not limited to, Lewy body dementia (LBD),
frontotemporal degeneration (FTD), vascular demen-
tia, and mixed dementias with the most common
being Alzheimer’s disease (AD), accounting for up to
two-thirds of the cases of dementia [1]. AD currently
affects 5.7 million Americans, and with an ever-
growing aging population it is expected to affect as
many as 13.8 million by 2050 [1, 2]. Death rates from
Alzheimer’s disease and related dementia (ADRD)
have more than doubled from 30.5 deaths per 100,000
in 2000 to 66.7 in 2017, with a precise pathogenesis
and effective treatment remaining unclear [3].
Current evidence suggests a significant overlap
between the phenotypes of dementia and their under-
lying pathoetiologies. For example, there exists a
vascular component present on histology in patients
with AD, LBD, and FTD, and amyloid- neuritic
plaques (A), neurofibrillary tangles, and Lewy bod-
ies may be found in any type of dementia. Due to
a similar clinical picture and pathophysiology AD,
vascular dementia, LBD, FTD, and mixed demen-
tia are included under the umbrella of ADRD [4, 5].
Current pharmacotherapies have been unsuccessful
in the reduction of morbidity and mortality associated
with ADRD, and at best, only temporarily improve
symptoms without successfully targeting the degen-
erative process [2]. Other treatment modalities, such
as dietary/nutritional supplements and lifestyle mod-
ifications, have also been investigated, but there still
remains insufficient evidence to support efficacy [2].
Investigation into other etiologic factors has
revealed a possible correlation between anemia and
ADRD [7–9]. Despite the wide-ranging severities
of anemia and its multiple subtypes, there is mini-
mal literature to define this association. We proposed
that there exists an association between ADRD and
anemia of chronic inflammation (ACI), and decided
to investigate the association between ADRD and
different subtypes of anemia, including ACI, iron




To define the relationship between anemia and
dementia, we conducted a retrospective case-control
observational study. A review of chart data was per-
formed on the electronic medical record at Brookdale
University Hospital Medical Center (Epic©EMR
Wisconsin, USA) on all patients that were seen
within the healthcare system as an outpatient at one
point in their clinical history from January 1, 2016
through January 1, 2019. Inclusion criteria were
defined as patients who had a diagnosis that fell
under the umbrella of ADRDs [Alzheimer’s dis-
ease (G30.0), vascular dementia (F01), dementia
with Lewy bodies (G31.83), frontotemporal dementia
(G31.0), or unspecified dementia (F03.0)]. Patients
with any other causes of symptomatology simi-
lar to that of dementia due to trauma, infection,
and anoxic/metabolic causes which included patients
with a diagnosis of diffuse traumatic brain injury
(S06.2), anoxic brain damage, not elsewhere clas-
sified (G93.1), Other and unspecified encephalopa-
thy (G93.4), metabolic encephalopathy (G93.41),
Parkinson’s disease (G20), Creutzfeldt-Jakob dis-
ease, unspecified (A81.00), and Huntington’s disease
(G10) were excluded from this study.
In efforts to ensure patients with anemia sec-
ondary to acute blood loss anemia were not
considered anyone with a diagnosis of upper and/or
lower gastrointestinal bleeding, genitourinary and/or
obstetrical bleeding, and traumatic bleeding were not
considered for the study. Patients with a diagno-
sis of malignancy were also not considered for the
study due to a high prevalence of malignancy and/or
chemotherapy related anemia in this patient popula-
tion [10]. Patients with hematological disorders such
as aplastic anemia, myelodysplastic syndrome, tha-
lassemia, or sickle cell anemia were also not included
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in the study as presence of these pathologies may act
as a cofounder. Patients with a diagnosis of HIV were
also not considered for the study due to higher preva-
lence of the anemia and dementia in this population
due to a different pathomechanism [11, 12].
In efforts to ensure that we conducted an age appro-
priate study, only patients with an age >60 were
included in the study as dementia in the younger pop-
ulation often carried a diagnosis/history that would
exclude the patient from the study. Controls were
defined as patients that were seen during the above-
mentioned specified time period that did not carry a
diagnosis of exclusion.
Definitions
Anemia was defined in accordance with the
adult World Health Organization (WHO) definition
of anemia, in terms of hemoglobin (Hb) which
included mild, moderate, and severe. For males
greater than 15 years of age, categories were as fol-
lows: mild 11.0–12.9 g/dL; moderate 8.0–10.9 g/dL;
severe <8.0 g/dL. For females, non-pregnant, greater
than 15 years of age, categories were as follows:
mild 11.0–11.9 g/dL, moderate 8.0–10.9 g/dL severe
<8.0 g/dL [13]. Additional information was obtained
from chart review to help specify category of anemia,
i.e., iron deficiency, vitamin B12, folate deficiency,
and anemia of ACI. For all patients with available
data, serum iron, total iron binding capacity (TIBC),
ferritin, vitamin B12, and folic acid was obtained.
To mitigate any confounding factors, serum creati-
nine (Cr) level and hemoglobin A1C (HgbA1C) were
obtained to rule out chronic kidney disease (CKD)
and diabetes mellitus (DM) as a possible cause of
ACI.
Statistical analysis
All the data are reported as sample means with
standard deviations. Pair-wise comparisons between
means of controls and cases in terms of Hb, iron,
TIBC, folic acid, vitamin B12, Cr, and HgbA1C
were performed using a Mann–Whitney U test where
the null hypothesis presuming means are equal was
tested. Statistical significance was defined as p value
<0.05.
Pair-wise comparisons between anemia subgroups
(moderate and severe) were performed using a Two
Sample proportion Z-Test, where for each couple of
normally distributed population, the null hypothesis
that the probability for event within each group is
identical was verified. Statistical significance in Two
Sample proportion Z-Test was defined as a p value
less than 0.05 and 95% confidence interval (CI) not
including one. Brookdale University Hospital Medi-
cal Center Institutional Review Board approval was
obtained for this study, IRB approval number 19/04.
RESULTS
A total of 4,517 patients (43% males; 57% females)
with a mean age of 75.6 ± 9.9 years were enrolled in
the study. Of those, 1,274 patients (42% males; 58%
females) with mean age of 80.8 ± 9.4 years with diag-
nosis of ADRD and 3,243 patients (44% males; 56%
females) with mean age of 73.5 ± 9.4 years without a
diagnosis of ADRD were included in the study based
on exclusion/inclusion criteria.
In our analysis, we examined nine clinical tests rel-
evant to the etiology of the anemia which have been
shown in Table 1. Pair-wise comparison of means
were analyzed using the Mann–Whitney U test,
which revealed that although both groups had low Hb
level, there was significant difference in Hb between
the ADRD and control group (10.15 g/dL versus
11.06 g/dL, p < 0.001, n = 4517). Both serum iron
level (64 ± 39.34 g/dL versus 53 ± 41.83 g/dL;
p < 0.001) and TIBC (225 ± 84.08 g/dL versus
266 ± 82.30 g/dL; p < 0.001) were found to be sig-
nificantly lower in the ADRD group compared to con-
trols. Ferritin level was elevated in only in the ADRD
Table 1
Laboratory data mean values in the clinical groups
Measurement (units) (reference range) ADRD group Control group p
Hb total (g/dL) (M: 13.5 to 17.5; F: 12.0 to 15.5) 10.15 ± 2.08 11.06 ± 2.08 <0.001
Serum Iron (ug/dL) (37.0–170.0) 64 ± 39.34 53 ± 41.83 <0.001
TIBC (ug/dL) (240–450) 225 ± 84.08 266 ± 82.30 <0.001
Ferritin (ng/mL) (11.10–264.00) 395 ± 488.18 263 ± 1023.4 <0.001
Vitamin B12 (pg/mL) (200–900) 726 ± 252.17 667 ± 248.26 <0.001
Folic acid (ng/mL) (2.76–20) 14.7 ± 5.38 14.3 ± 5.25 <0.05
Serum Creatinine (mg/dL) (0.52–1.04) 1.8 ± 1.82 1.7 ± 1.81 <0.05
Hb A1C (<6.5) 6.39 ± 1.51 6.42 ± 1.51 0.28
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(395 ± 488.18 ng/mL versus 263 ± 1023.4 ng/mL;
p < 0.001). Even though statistically significant, mean
folic acid and vitamin B12 levels were found to be
normal in both groups, suggesting no clinical rele-
vance. Similarly, serum creatinine was found to be
statistically significant between the two groups but
was without clinical relevance as the mean values
from both groups fell within the same clinical range of
kidney disease. There was no statistically significant
difference in HgbA1C between the groups (p = 0.28).
Graphical representation of pair-wise comparison of
laboratory data between clinical group is shown of
Fig. 1. Although both groups met the WHO defined
criteria for anemia, the degree was significantly worse
in the ADRD group. We compared moderate, severe,
and moderate-to-severe anemia subtypes across the
two groups, using a Two Sample proportion Z-Test.
Analysis revealed that severe anemia in ADRD group
was 6.2% higher than in controls [95% CI: 4.2–8.4],
and moderate anemia was 13% higher [95% CI:
9.8–16.2]. Overall, moderate-to-severe anemia was
found to be 19% higher in ADRD group [95% CI:
15.8–22.1] (Fig. 2). Giving the 7.3-year difference in
age between two clinical groups, there was a concern
that age would confound the comparisons. Therefore,
it was decided to compare the groups on Hb and iron
panel (Iron Level, ferritin, and TIBC) measures con-
trolling for age. Iron panel was chosen to investigate if
the association between ADRD and ACI is still valid
after controlling for age. The correlation between age
and TIBC was –0.16. and that between Age and Iron
Level, was –0.12. The correlation between Age and
Ferritin was –0.02. and that between Age and HGB
was –0.20. It is clear that the correlations between
Age and each of the measures were low. These
correlations suggest that adjusting for chronological
age would have little effect on the differences between
groups. In order to do the analysis, a multiple regres-
sion analysis was computed using Age and Group
(ADRD, Control) as predictors. A separate regres-
sion was computed for each measure (TIBC, ferritin,
iron level, and Hb). This test represents the difference
between the two groups, controlling for chronologi-
cal age. Table 2 contains the difference between the
groups without controlling for age and the differ-
ence between the two groups, controlling for age. In
this way, it is clear as to what effect adjusting for
Age would have on comparing the two groups on
each of the four measures. The differences are com-
puted by subtracting the mean of each measure of
the Control Group from the mean of each measure
of the ADRD Group. Therefore, a negative differ-
ence indicates that the mean for ADRD Group is
lower than that for the Control Group. The appropri-
ate standard errors are presented in parentheses with
each difference. The results of the test for regres-
sion weights are presented in Table 2 with the means
of measures mentioned above controlling for age in
Table 3. The results indicate that the ADRD Group
was significantly lower in TIBC, Iron Level, and Hb
and higher in Ferritin than the Control Group. There
are only small differences between the group dif-
ference with and without controlling for age. The
pattern of results along with magnitude of difference
are very similar whether one does or does not control
for age.
DISCUSSION
Our data suggests a clear statistically significant
association between ADRD and ACI, given low
serum iron and TIBC levels, elevated serum fer-
ritin with normal vitamin B12 and folic acid level in
ADRD group. We did not find statistical association
between HgbA1C and anemia in the ADRD group,
which excluded DM as the cause of ACI. Serum cre-
atinine also was not found to be clinically substantial,
which precludes CKD as contributor of ACI. These
findings suggest that there may be an independent
association between ADRD and ACI.
Anemia and ADRD
Preliminary reports of a possible association
between anemia and ADRD emerged in late 20th cen-
tury, and later has been strongly supported by large
prospective and retrospective studies [7, 8, 14–17].
In a prospective study from Hong et al., presence
of anemia was associated with developing of ADRD
(HR = 1.64; 95% CI: 1.30–2.07) [8]. This associa-
tion was confirmed with another prospective study
by Atti et al., demonstrating a two-fold increase in
incidence of dementia in patients with anemia within
3 years after adjusting for confounders like inflam-
mation, malnutrition and chronic disease (HR 1.6,
95% CI: 1.1–2.4) [15]. A large retrospective study by
Jeong et al. enrolled 37,900 persons and found sig-
nificant association between anemia and ADRD (HR
1.24; 95% CI: 1.02–1.51), and interestingly, hazard
ratio (HR) increased to 5.7 (95% CI: 1.84–17.81) for
patients with severe anemia [7]. Despite the strong
evidence of the general association, the relationship
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Fig. 1. Charts showing graphical representation of pair-wise comparison of laboratory data between clinical groups with respective p-values
shown in Table 1. A) Difference in Hg between two clinical groups is statistically significant. B) Difference in TIBC is statistically significant.
C) Difference in serum iron level is statistically significant. D) Difference in ferritin level is statistically significant. E. Difference in HgbA1C
is not statistically significant. F. Difference in Cr is statistically, but not clinically significant. G) Folic acid level was normal in both clinical
groups. H) B12 level was normal in both clinical groups.
between anemia subtypes and ADRD has remained
largely undefined, which could limit further research
for potential treatment options.
Smaller studies examining single subtypes of ane-
mia have also been presented. A case-control study
from Chung at el. found an association between IDA
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Fig. 2. Histogram illustrating significantly higher proportion of moderate and severe anemia in ADRD group (gray) in comparison to control
(blue) (95% CI: 15.8–22.1).
Table 2
Mean differences between groups without and with controlling for age and test of the
differences between groups controlling for age
Outcome Difference Difference between groups Test result
measure between groups controlling for age
TIBC –41.86 (2.72) –35.94 (2.88) t(4517) = –12.48, p < 0.001
Iron Level –10.63(1.35) –7.98 (1.43) t(4517) = –5.58, p < 0.001
Ferritin 132.41(22.81) 158.92 (24.11) t(4449) = 6.59, p < 0.001
HGB –0.91(.07) –0.68 (.07) t(4517) = –9.42, p < 0.001
Table 3
Means of the dementia group and the control group adjusting for
age
Measure Dementia group Control group
TIBC 229.13 265.07
Iron Level 54.98 62.96
Ferritin 414.00 255.08
HGB 10.32 11.00
and ADRD in females (OR 2.02, CI: 1.43–2.84),
but interestingly, no association was found in the
male population [18]. The study did not investigate
an association between other types of anemia aside
of IDA. Weuve et al. investigated the association
between ADRD and anemia with an elevated RDW,
which is usually associated with both IDA and ACI;
however, no statistically significant difference was
found (OR, 0.99; 95% CI: 0.86–1.18) [19]. In a retro-
spective study by Faux et al. an Australian Imaging,
Biomarkers and Lifestyle (AIBL) cohort was used
to investigate an association between anemia and
dementia in an Alzheimer’s population. The study
included 211 patients with AD, 133 patients with mild
cognitive impairment and 768 healthy adults [9, 20].
This study again showed a strong association between
anemia and ADRD (OR 2.43, CI: 1.31–4.54), but
more importantly, it was the first study which inves-
tigated a possible association between ADRD and
certain types of anemia. No statistically significant
differences were found between serum vitamin B12,
folic acid, serum Cr, blood urea nitrogen, and hap-
toglobin, which did not support an association ADRD
with some subtypes of anemia such as vitamin B12
and folic acid deficiency anemia, hemolytic anemia,
and anemia of CKD. Serum iron level was normal
in both groups, and ferritin was elevated in ADRD
group (p = 0.004), which does not support association
of IDA and ADRD. Anemia of chronic inflamma-
tion was considered by authors as candidate for
association, based on high ferritin and erythrocyte
sedimentation rate (ESR) (p = 0.006), but rejected
based on absence of statistically significant differ-
ences in serum iron, TIBC, transferrin saturation, and
interleukin-6.
Similarly, we found no association between ADRD
and IDA (in both the male and female population),
anemia of CKD, and vitamin B12 and folic acid defi-
ciency anemia. In contrast to Faux at el., we found a
statistically significant difference in serum iron, fer-
ritin and TIBC between the control and study groups.
Although normal in the control group, we found sig-
nificant evidence of iron dyshomeostasis and ACI in
ADRD group (low iron and TIBC levels, and high
ferritin level) (Table 1).
Though the association between anemia and
dementia has been well described in literature, the
pathophysiology of this association remains not well
understood. It has been hypothesized that anemia may
lead to memory loss due to chronic brain hypoxia
[7]. Alternatively, it has also been hypothesized that
it could be a sign of underlying ADRD and a reflec-
tion of a pathologic process that is yet understood.
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We found a strong association with ADRD and ACI,
which implies that a combination of anemia and iron
dyshomeostasis play a significant role in pathogene-
sis of dementia.
It is also important to mention that there have
been no long-term studies to assess the effect of
untreated anemia on the brain and memory func-
tion. We hypothesize that the brain, the most sensitive
organ to hypoperfusion and hypoxia, may require a
higher level of hemoglobin to maintain cortical func-
tions as we age. We found a significant difference of
almost 1 g/dL of Hb between the ADRD and con-
trol group (10.15 and 11.06, p < 0.001, N = 4,517).
Prevalence of moderate-to-severe anemia in ADRD
group was 19% higher as opposed to control group
[95% CI: 15.8–22.1]. In fact, blood transfusion goals
for anemia have been established based on guide-
lines determined by cardiovascular mortality and
morbidity data. According to current guidelines, the
transfusion goal for acute, symptomatic anemia is
set at hemoglobin level of 10 g/dL, and 7–8 g/dL
in asymptomatic hospitalized patients, as well as
in an outpatient setting [21–24]. In a meta-analysis
by Carson et al., there was no 30-day difference
in cardiovascular mortality and morbidity between
restrictive (Hb goal more than 8) group when com-
pared to liberal group (Hb goal more than 10) in terms
of blood transfusion [22]. These studies remain the
cornerstone of transfusion guidelines and treatment
of anemia, but there is strong possibility that the cere-
bral cortex requires a level of hemoglobin higher than
that of 7–8 g/dL to prevent development of ADRD.
Interestingly enough, Weiskopf et al. showed in their
study that a reduction of Hb level from 6 to 5 g/dL
produces subtle delays in reaction time and impaired
immediate and delayed memory, which reversed after
the subjects were transfused to a hemoglobin of above
7 g/dL [25].
If an acute reduction in Hb can cause such a change
in cognition, it is within reason to postulate that long
standing anemia may cause chronic damage to the
brain, contributing to memory loss and development
of dementia. Further prospective studies are needed to
determine, if blood transfusion targeting a Hb level of
more than 11 g/dL and/or correction of moderate-to-
severe anemia reduces the incidence or progression
of ADRD.
Anemia of chronic inflammation
Anemia of chronic inflammation (ACI), formerly
termed anemia of chronic disease, is defined as an
impaired production of erythrocytes due to inflam-
matory conditions such as chronic infection, cancer,
autoimmune diseases or milder but persistent inflam-
matory states such as DM, obesity, aging, and
CKD [26, 27]. A diagnosis of ACI requires nor-
mal iron stores with low circulation iron less than
60 g/dL, normal to low TIBC, serum ferritin more
than 12 ng/mL, or erythrocyte protoporphyrin con-
centration less than 1.24 microM [26, 27]. Chronic
inflammation increases ferritin levels, a marker of
stored iron; however, inability to use iron for ery-
thropoiesis in a state of chronic inflammation causes
“functional iron deficiency” [28]. Anemia of chronic
inflammation is frequently associated with inappro-
priately low levels of erythropoietin and elevated
measures of inflammatory markers, such as C-
reactive protein (CRP) [26].
Prevalence of anemia increases rapidly with age,
and in general 11.0% of men and 10.2% of women
65 years and older, and 20% of those greater than
85 years of age are found to be anemic [29]. As
was defined previously, ACI is frequently multifacto-
rial and commonly associated with chronic diseases,
including DM and CKD, and aging itself. Joosten et
al. observed 191 hospitalized elderly patients with
anemia, and showed that 70% of the patients had
ACI. 16% of the patients with ACI had concomi-
tant chronic renal failure, 71% of them had an
acute infection, 12% had cancer, and 16% had a
chronic infection, such as pressure ulcer, or a chronic
autoimmune inflammatory disease [30]. In addition, a
multi-center study with 4,892 ICU patients in United
States revealed that ACI is particularly common in
critically ill patients [31].
We investigated the association between ACI in
ADRD and CKD and did not find a clinical difference
in serum creatinine (1.8 mg/dL versus 1.7 mg/dL,
p < 0.001). Diabetes mellitus is another chronic con-
dition commonly associated with ACI [32]. HgbA1C
levels of both clinical groups were obtained, and
no significant difference was found (6.39% versus
6.42%, p = 0.28). Both conditions are among the most
common causes of ACI and it was essential to inves-
tigate their role as the potential confounders. As
laboratory sampling for both clinical groups were
obtained from outpatient clinic visits, it makes acute
illness less likely the cause of ACI. Present or past
history of cancer was one of the exclusion criteria for
this study making malignancy less likely to contribute
to ACI picture.
Blood transfusion, intravenous iron, and erythro-
poietin are established standards of care in treatment
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of ACI [26]. Administration of erythropoietin in
anemia has shown to be effective by elevating con-
centrations of reticulocytes and serum transferrin
receptors [33]. There is also novel experimental
therapy targeting IL-6 and hepcidin-ferroportin axis
[26]. Tocilizumab, an anti-IL6 receptor antibody,
has demonstrated efficacy in reduction of hepcidin
level and improving ACI in patients with rheuma-
toid arthritis. In addition, therapies targeting the
hepcidine-ferroportine axis include LDN-193189
and NOX-H94, these agents have shown to be effec-
tive in improvement of ACI in animal models.
Iron dyshomeostasis and ADRD
The phenomenon of iron dyshomeostasis in
patients with ADRD has been reported in multi-
ple studies, however the studies are of relatively
smaller sample size [34–43]. The role iron elements
play in AD could be theoretically established by try-
ing to quantify tissue concentrations as compared to
controls. In a postmortem case-control study of 16
patients by Grundke-Iqbal et al. ferritin was observed
in A plaques [35]. In addition, two in vivo studies
totaling 167 patients reported increased ferritin stor-
age in hippocampus and basal ganglia on of MRI
imaging of AD [39, 40]. Investigations have revealed
that there are increased concentrations of transfer-
rin in the post-mortem histopathologic studies of the
patients with AD [42, 43]. Interestingly, the total
concentration of iron in human brains with AD was
shown be to 67% higher in gray matter and 27%
higher in white matter as compared to control tis-
sue in postmortem study [43]. However, contrary to
the above-mentioned studies, in the large prospec-
tive study by Ayton et al., no difference in ferritin
level in CSF was found in cognitively normal patients,
patients with mild cognitive impairment, or ADRD
[44].
Evidence of iron dyshomeostasis in peripheral
blood associated with ADRD has been reported pre-
viously. In a systematic review by Lopes da Silva et
al. in 2014 with a total of 153 ADRD patients and 544
controls across five studies, only two studies showed
a statistically significant decrease in plasma iron lev-
els though the parameters of TIBC and ferritin levels
were not investigated [45]. Faux et al. used the AIBL
cohort to investigate the association between anemia
and dementia, and as was discussed earlier, was the
first study to investigate the association of all major
types of anemia with ADRD [9, 20]. No statistically
significant association was observed between specific
types of anemia and ADRD, but the authors, based on
elevated ESR and ferritin in ADRD group, proposed
an association with ACI. In 2017, a prospective study
by Goozee et al. showed statistically significant dif-
ference in serum ferritin in patients with preclinical
dementia with high neocortical A load, but serum
iron, TIBC, or Hb were not investigated [46]. In our
study, we were able to show a statistically significant
association between ACI and ADRD, which we theo-
rize is due to the higher power of our study compared
to previous reports.
While dysregulation of iron homeostasis in
patients with ADRD is evident, the exact origin of
excessive iron and ferritin stores as well as its precise
pathogenesis of its accumulation remain unclear. Iron
induced oxidative stress has been proposed and is well
supported in literature. Excess iron could promote the
conversion of hydrogen peroxide (H2O2) to hydroxyl
radical (–OH) with high toxic properties and trigger
A production, and thus, A plaques [34, 37, 38, 47].
Another intriguing hypothesis is that excessive iron
interferes with protein transcription and translation
in neurons and glial cells [38]. The cerebral cortex
has the largest iron storage in the body and iron-
regulation gene expression only second to the liver
as iron serves an essential role in myelin formation,
neurotransmitter production and metabolic activity
of the neurons [43]. There exists several proteins
involved in brain iron metabolism, including trans-
ferrin, transferrin receptor 1, ferritin, iron-regulatory
proteins (IRPs), ferroportin 1 (FPN1), lactoferrin,
divalent metal ion transporter, and brain-specific
ceruloplasmin [38, 44, 48, 49]. Iron and IRPs controls
transcription of these proteins in the brain via iron
regulatory element (IRE) located on mRNAs [50].
Interestingly, IRE was also found on amyloid- pro-
tein precursor (APP) mRNA, the direct progenitor
of A, and it has been postulated than APP itself can
further regulate iron metabolism, inducing influx of
the iron into the cell via FPN1 [50, 51]. Further excess
of iron accumulation leads to increase of aggregation
of APP, -synuclein, and A, matching the exact
pathogenesis that we see in ADRD.
Blocking IRE on APP, -synuclein, and A could
potentially prevent aggregation of misfolded pro-
teins. Several clinical trials are currently investigating
the role of IRE-inhibitors in ADRD and other neu-
rodegenerative disorders [49, 50]. Other promising
treatment molecule, targeting iron metabolism, is
lactoferrin, which was shown to be effective in reduc-
tion of A deposition and cognitive improvement
in mice in recent study [52]. Iron chelators, such
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as desferoxamine, deferasirox, and deferiprone, were
shown to be effective in mice and one small single-
blinded human study; however, potential significant
neurotoxicity is the major concern for using these
agents as a treatment for ADRD [53].
Inflammation, infection, and ADRD
Neuroinflammation plays a major role in the patho-
genesis of ADRD with involvement of microglia,
cytokines and complement complex [54]. One
hypothesis is that A peptides along with CD40 co-
stimulation trigger the inflammatory response [55].
Others have suggested that acute and/or chronic
inflammation can be transmitted to the brain via
cytokines acting on endothelial cells of the blood-
brain barrier. Subsequently a pro-inflammatory state
triggers A-dependent or A-independent inflamma-
tion inside the CNS, eventually leading to cognitive
impairment [56, 57]. Our study revealed changes in
the peripheral blood affecting complete blood count
and iron panel, suggesting chronic inflammation in
the patients affected by ADRD.
Association between inflammation and ADRD
is also well-supported in prior studies. In 2002,
Schmidt et al. published a large prospective study
which showed an association between elevated high-
sensitive CRP) and ADRD, and proposed that
inflammation precedes manifestation of dementia
[58]. In 2004, Engelhart et al. discovered that other
inflammatory proteins such as 1-antichymotrypsin
and IL-6 are associated with increased risk of ADRD;
relative risks were 1.49 (95% CI: 1.23–1.81) and 1.28
(95% CI: 1.06–1.55), respectively [59]. Yaffe et al.
observed a strong association between metabolic syn-
drome combined with inflammatory state (evident by
elevated IL-6 and CRP) and ADRD with RR of 1.69
[95% CI: 1.19–2.32] [60]. In a study by Holmes et
al. increases of tumor necrosis factor alpha, another
pro-inflammatory cytokine, in patients with ADRD
was associated with a fourfold increase in the rate
of cognitive decline over six months as compared to
the control group [61]. There also exists evidence of
the long-term association of a septic shock and res-
piratory failure with cognitive impairment [62, 63].
Summary of the studies that elucidated the evidence
of association between inflammation and ADRD are
illustrated in the Table 4.
A deposition has been considered the major force
behind ADRD pathophysiology, and, specifically,
AD [64]. However, there is a growing body of lit-
erature that suggests that role of A in neuronal
damage might be misunderstood as new evidence
is suggestive of a protective role [57, 65]. Recent
in vitro and in vivo studies have revealed antibacte-
rial and antifungal properties of A [66]. Therapies
targeting A reduction have not produced clinical
improvement in cognition or successfully decreased
A level [67, 68]. Adverse effects of anti-A ther-
apy included increased infection rates, including
meningioencephalitis after active immunotherapy
against A, and relapse of herpes infection in
patients received -site APP cleaving enzyme and
-secretase inhibitors [65].
Evidence of inflammation and antimicrobial prop-
erties A have led to further research in this area.
Emerging data strongly point to the evidence of
infection etiologies of the ADRD, including viral,
bacterial, and fungal origin [65, 69, 70]. Recent
in vitro studies have shown that A demonstrates
antimicrobial activity against at least eleven micro-
bial pathogen, including Herpes Simplex Virus 1 and
Table 4
Summary of the studies of association of the inflammation and ADRD











Association between elevated alpha1-antichymotrypsin, interleukin-6
and ADRD (RR 1.49, 95% CI: 1.23–1.81; RR 1.28, 95% CI: 1.06–1.55)




Association between metabolic syndrome with inflammation and





Association with progression of ADRD in group with high baseline
TNF-levels and presence of systemic inflammatory events (p = 0.02)




Presence of any joint disorder in midlife associated with worse





Longer duration of delirium during ICU stay is associated with worse
global cognition and executive function (p = 0.004)
hsCRP, high-sensitivity C-reactive protein; ADRD, Alzheimer’s disease and related dementia; TNF, tumor necrosis factor; CI, confidence
intervals; RR, relative risk.
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Table 5
Summary of the studies of association of the infection and ADRD
Study Study design Findings
Pisa, 2015 [70] Postmortem Immunohistochemical analyses of the brain tissue from AD patients showed intracellular




Meta-analysis Ten-fold increase in risk of occurrence of AD with presence of spirochetal infection (OR:
10.61; 95% CI: 3.38–33.29). Five-fold increase in rick of occurrence of AD with presence of
Chlamydophila infection (OR: 5.66; 95% CI: 1.83–17.51)
Pisa, 2016 [73] Postmortem Presence of fungal proteins, enolase and -tubulin, and polysaccharide chitin in tissue sample
from AD patients
Alonso, 2017 [74] Postmortem Next-generation sequencing revealed fungal species Alternaria, Botrytis, Candida,
Cladosporium, and Malassezia in the tissue of entorhinal cortex and hippocampus of the
patient with ADRD
Tzeng, 2018 [71] Retrospective
cohort study
Adjusted HR of 2.564 (95% CI: 2.351–2.795, p < 0.001) for development of ADRD in
HSV-infected cohort versus non-HSV cohort. Treatment with anti-herpetic medication showed
reduction of dementia development (adjusted HR = 0.092 [95% CI 0.079–0.108], p < 0.001).
AD, Alzheimer’s disease; HSV, herpes simplex virus; OR, odds ratio; HR, hazard ratio; CI, confidence intervals.
2 (HSV1 and HSV2), Influenza A, Escherichia coli,
Enterococcus faecalis, Staphylococcus aureus, and
Streptococcus pneumonie [65]. In 2017, Emery at al.
published a study using 16S ribosomal gene-specific
next generation sequencing (NGS) of postmortem
brains, which revealed five to ten-fold increase in bac-
terial load in patients with ADRD in comparison to
controls. A large retrospective cohort study by Tzeng
et al. elucidated significant risk reduction in ADRD
development in patients affected by HSV treated with
antiherpetic medication (adjusted HR = 0.092, 95%
CI: 0.079–0.108, p < 0.001) [71]. In 2015, Mahesh-
wari et al. conducted a meta-analysis, which found
five-fold increase occurrence of ADRD in patients
with Chlamydia pneumonia in comparison to con-
trol groups (OR: 5.66; 95% CI: 1.83–17.51) [72]. In
addition, majority of the patients with ADRD die
from pneumonia as an immediate cause of death
[69]. There is a growing body of evidence to support
an association between ADRD and fungal infection;
fungal Enolase, -Tubulin, and Chitin was identi-
fied in the brain samples of the patients with ADRD,
and this evidence was recently advanced by detec-
tion of the fungal DNA the frozen brain tissue of the
patients with ADRD using NGS [73, 74]. Summary
of the studies that elucidated evidence of associa-
tion with microbial infection are presented in the
Table 5.
Limitations of the study
There were certain limitations of this study. The
retrospective nature of the study allowed us to show
an association between ACI and ADRD but not cau-
sation. Elevations in ESR and CRP are laboratory
markers of the ACI in addition to Hb and iron profile,
but these markers were not available for investigation.
Autoimmune disease, such as rheumatoid arthritis
and systemic lupus erythematosus can lead to ACI;
however, association with ADRD, ACI, and rheuma-
tologic disorders were not investigated in this study
due to relatively low prevalence in the population
(prevalence of rheumatoid arthritis in the US is 0.55%
[75]; prevalence of systemic lupus erythematosus is
0.006% [76]).
Conclusion
There exists a fair amount of literature examining
the role of anemia in ADRD though not one study
encompasses a global view of anemias in their
analysis. We chose to investigate the subtypes
of anemia and its role in dementia. We found a
statistically and clinically significant decrease in the
Hb level between ADRD group and control groups
(p < 0.001). We also observed the proportion of
moderate and severe anemia was significantly higher
in ADRD group (95% CI: 15.8–22.1). Analysis
of iron studies revealed that ACI has the strongest
association with ADRD, independent of CKD and
DM. We did not find association between ADRD and
IDA, vitamin B12 or folic acid deficiency anemia.
These findings suggest blood transfusion to target
Hb of ≥11 mg/dL and/or correction of moderate-
to-severe anemia could be investigated as potential
therapeutic interventions. Correction of ACI with
erythropoietin and/or intravenous iron administra-
tion, and treating chronic infections also warrant
consideration in future studies. Further prospective
studies to establish a causative link in addition
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to clinical trials are required to corroborate out
findings.
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